Samsung Biologics Stocks Fall 6.78% After 3 Trillion Won Capital Increase Plan
Samsung Biologics submitted a securities registration on the 28th for a 3 trillion won capital increase through a rights offering to existing shareholders followed by a public offering of unsubscribed shares. According to the electronic disclosure system, the company plans to issue 2.27 million
GateMacroTradfiHub·08-28 09:51
